The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

qstatebio.com

Founded Year

2013

Stage

Series B | Alive

Total Raised

$31.22M

Last Raised

$21.22M | 3 yrs ago

Mosaic Score

+20 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Q-State Biosciences

Q-State Biosciences is a precision medicine company creating new genetically targeted medicines for people living with nervous system disorders. The company's proprietary ResQueTM Platform incorporates a suite of technologies to map each patient’s unique genome to a genetic therapy that targets the root cause of disease.

Q-State Biosciences Headquarter Location

179 Sidney Street

Cambridge, Massachusetts, 02139,

United States

617-945-5433

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Q-State Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Q-State Biosciences is included in 3 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Q-State Biosciences Patents

Q-State Biosciences has filed 14 patents.

The 3 most popular patent topics include:

  • Genetics
  • Molecular biology
  • Neurological disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/13/2018

4/7/2020

Rare diseases, Neurological disorders, Ion channels, Syndromes, Genetics

Grant

Application Date

9/13/2018

Grant Date

4/7/2020

Title

Related Topics

Rare diseases, Neurological disorders, Ion channels, Syndromes, Genetics

Status

Grant

Latest Q-State Biosciences News

Q-State Biosciences Announces New Peer Reviewed Publication Introducing Its Next Generation Swarm™ Optogenetic Measurement Technology System

Jul 13, 2022

July 13, 2022 09:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of serious central nervous system disorders, announced today the publication of a peer reviewed original research article in Frontiers in Molecular Neuroscience. The paper, titled “ Highly Parallelized, Multicolor Optogenetic Recordings of Cellular Activity for Therapeutic Discovery Applications in Ion Channels and Disease-associated Excitable Cells ,” highlights Q-State’s proprietary Swarm™ technology system. A pillar of the company’s unique-in-world BRITE™ discovery engine, Swarm™ leverages highly parallelized optogenetic measurements of human and animal model systems to characterize complex cellular function and the performance characteristics of therapeutic candidate molecules. The publication is part of a special research topic collection entitled “Targeting Ion Channels for Drug Discovery: Emerging Challenges for High Throughput Screening Technologies.” The paper details the design and operating capabilities of the new Swarm™ system, including its use applications in neuronal and cardiac model systems to broadly quantify cellular activity. As a demonstration of the system’s high throughput capacity, Q-State scientists established and optimized a series of ‘Spiking HEK’ cell assays to screen voltage-gated sodium channel subtypes such as Nav1.7, which plays a critical role in the sensory transmission of pain and has historically been a challenging target for drug development. The team at Q-state first validated the instrument and assays with known pharmacological tool compounds and then performed a high-throughput screen of 200,000 small molecules to identify Nav1.7 subtype selective blockers to show its utility at scale. As a final demonstration of the versatility of Swarm™, the new system was used to record changes in both voltage and calcium simultaneously in human iPSC-derived cardiomyocytes under paced conditions. This state-of-the-art approach represents significant progress in the ability to screen challenging but biologically important drug targets with the throughput, deep information content, and high temporal resolution necessary to power AI/ML-based computational insights which will ultimately yield urgently needed new therapies to patients. Q-State technologist Gabriel Borja is lead author of the paper. About Q-State Biosciences Q-State Biosciences is a technology-enabled therapeutics company that applies its proprietary, unique-in-world BRITE™ discovery engine to identify genetically targeted therapeutics for neurodevelopmental, neurodegenerative and other serious disorders of the CNS. By integrating our advanced human neuronal models, custom measurement bioengineering, computational neuroscience, and powerful AI/machine learning, we create the unique, ultra-large neuronal datasets necessary to unlock unique insights into the biological complexity of the brain, its associated disease states, and the creation of transformational medicines. For more information, please visit www.qstatebio.com . Contacts

Q-State Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Q-State Biosciences Rank

  • When was Q-State Biosciences founded?

    Q-State Biosciences was founded in 2013.

  • Where is Q-State Biosciences's headquarters?

    Q-State Biosciences's headquarters is located at 179 Sidney Street, Cambridge.

  • What is Q-State Biosciences's latest funding round?

    Q-State Biosciences's latest funding round is Series B.

  • How much did Q-State Biosciences raise?

    Q-State Biosciences raised a total of $31.22M.

  • Who are the investors of Q-State Biosciences?

    Investors of Q-State Biosciences include Small Business Innovation Research Awards.

  • Who are Q-State Biosciences's competitors?

    Competitors of Q-State Biosciences include PierianDx and 7 more.

You May Also Like

Semalytix Logo
Semalytix

Semalytix offers pharmaceutical companies an AI-powered data tool to better understand real-world patient experiences. Its flagship product, dubbed "Pharos", is a patient research tool that pulls in and cleans up various unstructured public data -- such as blogs, forums, social media etc. -- and then applies algorithms to deliver real-time patient insights into unmet needs, treatment experience, and how severely a disease impacts the lives of those who suffer from it.

Validic Logo
Validic

Motivation Science is the developer of Validic, a digital health platform that provides a simple connection to secure, standardized data from specialized digital health technologies, such as wellness applications, wearables, fitness equipment and clinical devices.

Inflammatix Logo
Inflammatix

Inflammatix is a molecular diagnostics company that develops rapid tests that read the immune system to resolve major clinical and public health challenges. The company's initial focus is on acute bacterial, viral infections, and sepsis.

Beacon Biomedical Logo
Beacon Biomedical

Beacon Biomedical is a medical diagnostic development and a Centers of Medicare and Medicaid Services (CMS) CLIA accredited laboratory services company providing easy, accurate, and affordable blood tests for earlier cancer detection. Its laboratory-developed test (LDT) solutions are developed for healthcare practitioners and individuals alike and are intended to be used as screening tests for the presence of undiagnosed cancer. They are specifically designed for those who are unwilling or unable to participate in cancer screening using current procedures and tests. The company's focus is on providing blood-based cancer screening alternatives in order to improve screening participation and earlier detection of these devastating diseases.

P
Pentavere Research Group

Pentavere is an early-stage digital health company working with 6 of the top-10 largest pharmaceutical in the world. The company is the developer of a proprietary artificial intelligence (AI) engine that is proven and validated to transform complex clinical documentation into usable real-world evidence and lifesaving insights. Pentavere’s big pharma customers have deployed its AI technology across their entire value chains to inform strategic decisions and enhance clinical workflows, improving operational efficiencies and saving significant costs. The company was founded in 2016 and is based in Toronto, Ontario.

A
Accellix

Accellix develops fully automated, cost-effective, actionable cell-based analysis, 24/7 at the point of need, to a broad range of users. Its Accellix single-use cartridge analysis system provides results in less than 30 minutes, requires minimal training, and does not require users to deal with biological reagents, sample preparation, and complex data analysis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.